Skip to main content
. 2006 Oct;50(10):3367–3374. doi: 10.1128/AAC.00593-06

FIG. 1.

FIG. 1.

Biochemical analysis of DC-SIGN binding component in human milk. (A) The DC-SIGN-Fc binding capacity of trypsin-treated human milk (HM) (end concentration, 1/40) was measured by DC-SIGN-Fc binding ELISA. The DC-SIGN-Fc binding background level was obtained by preincubation with AZN-D1 (DC-SIGN-specific blocking antibody) and EGTA. * represents a P value of <0.01 compared to the binding of the human milk incubated with RPMI. (B) Raji-DC-SIGN cells were incubated with the trypsin-treated human milk or controls in the presence of HIV-1 before being washed and before CD4+ T lymphocytes were added. As a control, Raji or Raji-DC-SIGN cells were incubated with PBS and virus before the addition of CD4+ T lymphocytes. CA-p24 production was measured at day 7 by standard ELISA. * represents a P value of <0.01 for inhibition compared to that of Raji-DC-SIGN. (C) Human milk (dilution, 1:2) was heated at 99°C for 10 min before the determination of the DC-SIGN-Fc binding capacity. AZN-D1 and EGTA were used as controls to show DC-SIGN-Fc-specific binding. * represents a P value of <0.001 in comparing heat-treated milk to a nontreated sample. Standard deviations are depicted in all graphs.